Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis

被引:9
|
作者
Ju, Young-Cheol [1 ]
Jun, Dae-Won [1 ,2 ]
Choi, Jun [3 ]
Saeed, Waciar Khalid [2 ]
Lee, Hyo-Young [2 ]
Oh, Hyun-Woo [2 ]
机构
[1] Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Translat Med, Seoul 04763, South Korea
[2] Hanyang Univ, Sch Med, Dept Internal Med, 222 Wangsimni Ro, Seoul 04763, South Korea
[3] Korea Univ, Dept Ind Management Engn, Seoul 02841, South Korea
关键词
Hepatitis B; Antiviral agent; Decompensated cirrhosis; Mortality; Hepatocellular carcinoma; VIRUS-RELATED CIRRHOSIS; HEPATOCELLULAR-CARCINOMA; LIVER-TRANSPLANTATION; PROGNOSTIC INDICATORS; NATURAL-HISTORY; ENTECAVIR; LAMIVUDINE; SURVIVAL; METAANALYSIS; DISEASE;
D O I
10.3748/wjg.v24.i40.4606
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To investigate survival rate and incidence of hepatocellular carcinoma (HCC) in patients with decompensated cirrhosis in the antiviral era. METHODS We used the Korean Health Insurance Review and Assessment. Korea's health insurance system is a public single-payer system. The study population consisted of 286871 patients who were prescribed hepatitis B antiviral therapy for the first time between 2007 and 2014 in accordance with the insurance guidelines. Overall, 48365 antiviral treatment-naive patients treated between 2008 and 2009 were included, and each had a follow-up period >= 5 years. Data were analyzed for the 1 st decompensated chronic hepatitis B (CHB) and treatment-naive patients (n = 7166). RESULTS The mean patient age was 43.5 years. The annual mortality rates were 2.4%-19.1%, and 5-year cumulative mortality rate was 32.6% in 1 st decompensated CHB treatment-naive subjects. But the annual mortality rates sharply decreased to 3.4% (2.4%-4.9%, 2-5 year) after one year of antiviral treatment. Incidence of HCC at first year was 14.3%, the annual incidence of HCC decreased to 2.5% (1.8%-3.7%, 2-5 year) after one year. 5-year cumulative incidence of HCC was 24.1%. Recurrence rate of decompensated event was 46.9% at first year, but the annual incidence of second decompensation events in decompensated CHB treatment-naive patients was 3.4% (2.1%-5.4%, 2-5 year) after one year antiviral treatment. 5-year cumulative recurrence rate of decompensated events was 60.6%. Meanwhile, 5-year cumulative mortality rate was 3.1%, and 5-year cumulative incidence of HCC was 11.5% in compensated CHB treatment-naive patients. CONCLUSION Long term outcome of decompensated cirrhosis treated with antiviral agent improved much, and incidence of hepatocellular carcinoma and mortality sharply decreased after one year treatment.
引用
收藏
页码:4606 / 4614
页数:9
相关论文
共 50 条
  • [1] Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
    Young-Cheol Ju
    Dae-Won Jun
    Jun Choi
    Waqar Khalid Saeed
    Hyo-Young Lee
    Hyun-Woo Oh
    [J]. World Journal of Gastroenterology, 2018, (40) : 4606 - 4614
  • [2] Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis
    Iacobellis, Angelo
    Perri, Francesco
    Valvano, Maria Rosa
    Caruso, Nazario
    Niro, Grazia Anna
    Andriulli, Angelo
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (03) : 249 - 253
  • [3] Antiviral therapy of patients with decompensated cirrhosis associated with hepatitis C virus infection
    Ji, F. P.
    Deng, H.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2011, 15 : S83 - S83
  • [4] Antiviral Therapy in Decompensated Cirrhosis due to Hepatitis B Virus
    Fu, Qingchun
    Chen, Chengwei
    [J]. GUT AND LIVER, 2011, 174 : 123 - 126
  • [5] Positive impact of antiviral therapy on the long term outcome of chronic hepatitis C patients with cirrhosis
    Cardoso, Ana C.
    Moucari, Rami
    Boyer, Nathalie
    Asselah, Tarik
    Laatar, Asma
    Ripault, Marie-Pierre
    Martinot-Peignoux, Michele
    Maylin, Sarah
    Bedossa, Pierre
    Marcellin, Patrick
    [J]. HEPATOLOGY, 2007, 46 (04) : 346A - 346A
  • [6] Antiviral therapy of decompensated hepatitis B virus-related cirrhosis
    Chen Guang-cheng
    Yu Tao
    Huang Kai-hong
    Chen Qi-kui
    [J]. CHINESE MEDICAL JOURNAL, 2012, 125 (02) : 373 - 377
  • [7] Antiviral therapy for hepatitis B virus-related decompensated cirrhosis
    Wang, Ji Yao
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2012, 13 (11) : 555 - 557
  • [8] ANTIVIRAL THERAPY FOR THE PREVENTION OF LONG-TERM CIRRHOSIS RISK IN PATIENTS WITH CHRONIC HEPATITIS B
    Yang, H. -I.
    Hoang, J.
    Lin, D.
    Liu, J.
    Hu, H. -H.
    Lee, M. -H.
    Nguyen, N. H.
    Kim, Y.
    Jen, C. -L.
    Vu, V.
    Le, A.
    Chaung, K.
    Nguyen, V.
    Trinh, H.
    Li, J.
    Zhang, J.
    Hsing, A.
    Chen, C. -J.
    Nguyen, M. H.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S591 - S591
  • [9] Antiviral therapy of decompensated hepatitis B virus-related cirrhosis
    CHEN Guang-cheng
    YU Tao
    HUANG Kai-hong
    CHEN Qi-kui
    [J]. 中华医学杂志(英文版), 2012, (02) : 373 - 377
  • [10] Safety and efficacy of antiviral therapy in patients with decompensated cirrhosis associated with chronic hepatitis C infection
    Lim, JK
    Imperial, JC
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 : 211 - 211